Cite
Liberti L, Bujar M, Breckenridge A, et al. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Front Pharmacol. 2017;8:161doi: 10.3389/fphar.2017.00161.
Liberti, L., Bujar, M., Breckenridge, A., Hoekman, J., McAuslane, N., Stolk, P., & Leufkens, H. (2017). FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Frontiers in pharmacology, 8161. https://doi.org/10.3389/fphar.2017.00161
Liberti, Lawrence, et al. "FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines." Frontiers in pharmacology vol. 8 (2017): 161. doi: https://doi.org/10.3389/fphar.2017.00161
Liberti L, Bujar M, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Front Pharmacol. 2017 Apr 03;8:161. doi: 10.3389/fphar.2017.00161. eCollection 2017. PMID: 28420989; PMCID: PMC5376616.
Copy
Download .nbib